Innovative Lysozyme-based ingredient
As a global leader in hen egg white lysozyme, Bioseutica is expanding its portfolio with LysOHT®, an innovative lysozyme-based ingredient designed to support human and environmental health. LysOHT® is intended for use in formulations addressing challenges related to coronavirus infections, leveraging lysozyme’s well-characterized antiviral and immune-supporting properties. The development of LysOHT® builds upon Bioseutica’s extensive experience in the production of natural, high-purity lysozyme and its commitment to advancing science-driven, sustainable solutions.
Scientific Background
SARS-CoV-2 is an enveloped β-coronavirus responsible for COVID-19. It is characterized by a lipid bilayer envelope, a spike glycoprotein mediating host cell entry, and a single-stranded RNA genome, with particles approximately 80–90 nm in diameter. Among the numerous variants identified during the pandemic, the B.1 lineage carrying the D614G spike mutation became globally dominant by mid-2020 due to enhanced transmissibility and rapid spread across Europe and other continents. The antiviral activity of LysOHT® was evaluated in vitro in collaboration with the prestigious University of Milan (Italy), using the SARS-CoV-2 B.1 lineage with the D614G spike mutation. The study demonstrated that LysOHT® is effective in reducing viral replication under controlled laboratory conditions, highlighting its potential as an active ingredient for formulation development. Although conventional lysozyme is widely recognized for antibacterial and antiviral properties, it has not demonstrated significant antiviral activity against SARS-CoV-2 in standard Vero cell assays. LysOHT® shows measurable antiviral activity under controlled laboratory conditions.
What makes LysOHT® Unique
LysOHT® represents a novel lysozyme-based ingredient with a differentiated functional profile. Its unique characteristics make it suitable for advanced pharmaceutical, medical device, and disinfectant/biocidal formulations.
Key Experimental Findings (Vero Cell Studies):
- Therapeutic activity: inhibits SARS-CoV-2 replication in cells already infected with the virus.
- Prophylactic activity: reduces viral infection in non-infected cells exposed to the virus.
- Dose-dependent antiviral effects: measurable activity within the range of 1.0–1.5 mg/mL (0.1-0.15% w/v)
Additional Differentiators of LysOHT®:
- Safety: derived from hen egg white lysozyme, the natural occurring enzyme with a long history of safe use in food, pharmaceutical and healthcare applications.
- Stability: maintains functional integrity under controlled processing conditions.
- Solubility: high aqueous solubility, enabling incorporation into diverse pharmaceutical, topical and surface-treatment systems.
- Dual functionality: newly demonstrated antiviral activity with preserved antibacterial enzymatic activity, offering multi-functional protection.
- Natural origin and clean-label: suitable for vegetarian-friendly formulations and eco-conscious product development
Together, these properties make LysOHT® a highly differentiated lysozyme-based ingredient, combining natural origin, functional versatility, and scientifically demonstrated antiviral and antibacterial performance
Intended Applications
Subject to applicable regulatory requirements in the relevant jurisdictions, LysOHT® is suitable for integration into multiple product categories:
Pharmaceuticals
LysOHT® provides a novel lysozyme-based ingredient for the development of products targeting viral respiratory infections.
Potential applications include (subject to further safety and efficacy evaluation):
- medicinal products with various routes of administration, including cutaneous and oral applications
- Topical formulations for oral and nasal use designed to support protective barriers functions at mucosal surface, which are primary entry points for respiratory viruses.
Disinfectants and biocidal products
LysOHT® can serve as an active component in next-generation disinfectant and biocidal formulations. Its dual antibacterial and antiviral functionality, aqueous solubility, and natural protein-based origin support environmentally responsible hygiene solutions, enabling more sustainable and safe cleaning and surface-protection strategies. Medical Devices LysOHT® may be incorporated as an active ingredient in medical device formulations where antimicrobial and antiviral functionality is desired.
Potential applications include:
- nasal sprays, oral gels, wound care products, ophthalmic devices, and other surface- or mucosa-targeted systems used in healthcare settings.
LysOHT® Usage Environments
- Healthcare and medical settings: hospitals, healthcare facilities, community medical centres, dental practices and long-term care or nursing homes.
- Educational and Professional Environments: schools, kindergartens, workplaces and other high-traffic public areas.
- Domestic and Consumer Environments: households, including kitchens, laundries, and surfaces associated with care products for vulnerable individuals.
LysOHT® Features
-
Origin:
lysozyme-based ingredient derived from hen egg white, manufactured by Bioseutica using proprietary patented processing technology.
-
Activity profile:
demonstrated antiviral activity against SARS-CoV-2 in vitro using Vero cell models and retained antibacterial enzymatic activity.
-
Mode of action (based on in vitro experimental data):
inhibition of viral replication in infected cells and reduction of viral infection in non-infected cells exposed to SARS-CoV-2.
-
Effective concentration range:
1.0–1.5 mg/mL (0.1 – 0.15% w/v) in in-vitro study, dose-dependent effect
-
Functional Characteristics:
retention of antibacterial enzymatic activity, high aqueous solubility, natural protein origin with well-established use history in food and healthcare applications
-
Positioning:
patent-protected, differentiated/unique product, ideal for pharmaceutical, disinfectant/biocidal and medical device formulations, clean-label, vegetarian-friendly, natural product.
Intellectual Property
Bioseutica®’s rights to LysOHT® are secured by a dedicated patent portfolio covering its use, alone or in combination with Ovotransferrin, in antiviral applications against SARS-CoV-2. The portfolio includes an international patent family originating from application WO2021229430, which relates to the antiviral use of heat-treated lysozyme compositions, including LysOHT®.
Bioseutica®: Your Partner In Global Health
Bioseutica® is a global leader in the supply of natural products and specialty ingredients across food, pharmaceutical, feed, biocidal, medical devices and plant protection industries, combining scientific innovation with a strong commitment to environmental sustainability. With LysOHT®, Bioseutica® extends its expertise into antiviral innovation, offering high-quality, science-driven products supported by advanced manufacturing capabilities, reliable continuous supply, and robust quality assurance, ensuring that partners can rely on consistent, trustworthy products for their formulation development. Our eco-conscious practices further reinforce our commitment to safe, sustainable solutions.
Partnership & Collaborations
Bioseutica® welcomes collaborations with industrial partners, research institutes, and Companies to explore LysOHT®-based applications. For information, licensing opportunities or partnerships, please contact us through the webform on our dedicated page: Business Development